SCHEMBL758887

SCHEMBL758887

C=CC=CC=CCCCCCCC=CC=CCC=CC=CCC=CC=CCC(=O)C=CC

nearest known ligand 0.43

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ALOX12 P18054 3/20 0.43
ALOX15 P16050 1/20 0.43
OXER1 Q8TDS5 4/20 0.36
KDM4E B2RXH2 1/20 0.35
SOAT1 P35610 1/20 0.35
FASN P49327 1/20 0.34
ALOX5 P09917 1/20 0.34
ALDH1A1 P00352 2/20 0.33
MAPT P10636 1/20 0.33
CNR1 P21554 2/20 0.31
CNR2 P34972 2/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL758886 1.00 ALOX12 (0.43) ALOX12ALOX15OXER1KDM4ESOAT1
SCHEMBL25235157 0.76 PPARG (0.36) KDM4ESOAT1FASNCNR1CNR2
SCHEMBL28953206 0.73 CNR2 (0.40) ALOX12ALOX15SOAT1ALDH1A1CNR1
SCHEMBL31754718 0.71 ALOX15 (0.38) ALOX12ALOX15ALDH1A1MAPTCNR1
SCHEMBL5555328 0.69 TSHR (0.39) SOAT1FASNALDH1A1MAPTTSHR
SCHEMBL8621883 0.69 TSHR (0.39) SOAT1FASNALDH1A1MAPTTSHR
Bicarbonate SCHEMBL5173009 0.69 FASN (0.62) ALOX15KDM4EFASNALDH1A1MAPT
Hydrochloric Acid SCHEMBL31754477 0.69
Bicarbonate SCHEMBL7291479 0.69 FASN (0.62) ALOX15KDM4EFASNALDH1A1MAPT
SCHEMBL16090843 0.69 FASN (0.49) ALOX15KDM4ESOAT1FASNMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399473-B2 Macrocyclic spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease Merck, Sharp & Dohme, Corp. (US) 2013-03-19 US claimed
EP-2073635-B1 MACROCYCLIC SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME (US) 2012-03-21 EP claimed
US-20100029701-A1 MACROCYCLIC SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME LLC 2010-02-04 US claimed
US-8399473-B2 Macrocyclic spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease Merck, Sharp & Dohme, Corp. (US) 2013-03-19 US disclosed
EP-2073635-B1 MACROCYCLIC SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME (US) 2012-03-21 EP disclosed
US-20100029701-A1 MACROCYCLIC SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME LLC 2010-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029701-A1 MACROCYCLIC SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE BACE1, BACE2, APP ALOX12 2301/4885ALOX15 1966/4885OXER1 1312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.